Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Symptoms of Toxicity and Plasma Cytochrome c Levels in Human Immunodeficiency Virus-infected Patients Receiving Anti-retroviral Therapy in Ghana: A Cross-sectional Study

Author(s): Eric A. Mensah, Bismark Sarfo, Evelyn Y. Bonney, Prince K. Parbie and Augustine Ocloo*

Volume 20, Issue 1, 2020

Page: [88 - 97] Pages: 10

DOI: 10.2174/1871526518666181102112010

Price: $65

Abstract

Background: Side effects and toxicity have posed a threat to the positive contribution of Antiretroviral Therapy (ART) in the management of human immunodeficiency virus (HIV) infection and Acquired Immune Deficiency Syndrome (AIDS). Symptoms of mitochondrial toxicity including myopathy, pancreatitis, hyperlipidaemia and lactic acidosis are found among HIVinfected patients on ART. To date, there is not a reliable biomarker for monitoring ART-related mitochondrial toxicity. Plasma level of Cytochrome c (Cyt-c) has been proposed as a potential biomarker for ART-related toxicity due to its strong association with apoptosis.

Objective: The present study assessed toxicity and level of plasma Cyt-c among HIV-infected patients receiving ART in Ghana.

Methods: A total of eighty (80) HIV patients were recruited into the study. Demographic data were obtained from personal interview and medical records. Plasma samples were screened for toxicity from sixty (60) participants due to limited resources, and plasma Cyt-c levels were determined using ELISA. Data were analyzed using Stata version 13.

Results: Out of the 60 participants, 11 (18.3%) were found with symptoms of myopathy, 12 (20%) with pancreatitis, 21 (35%) with hyperlipidaemia and 36 (60%) with at least one of the symptoms. The concentration of plasma Cyt-c was higher (0.122 ng/ml) in patients with toxicity than in those without toxicity (0.05 ng/ml), though the difference was not statistically significant (p = 0.148). There was a weak correlation between plasma Cyt-c level and duration of ART (Spearman rho = 0.02, p = 0.89).

Conclusion: This study, therefore, demonstrated a high prevalence of ART-related toxicity and high levels of Cyt-c in HIV-infected patients in support of the argument that plasma Cyt-c levels are potential biomarkers for determining ART-related toxicity in HIV patients.

Keywords: ART, Toxicity, plasma cytochrome c, AIDS, mitochondrial toxicity, HIV-infection, hyperlipidaemia.

Graphical Abstract

[1]
Anderson, P.L.; Kakuda, T.N.; Lichtenstein, K.A. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis., 2004, 38(5), 743-753.
[http://dx.doi.org/10.1086/381678] [PMID: 14986261]
[2]
Maagaard, A.; Kvale, D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J. Antimicrob. Chemother., 2009, 64(5), 901-909.
[http://dx.doi.org/10.1093/jac/dkp316] [PMID: 19740910]
[3]
Kakuda, T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther., 2000, 22(6), 685-708.
[http://dx.doi.org/10.1016/S0149-2918(00)90004-3] [PMID: 10929917]
[4]
Chariot, P.; Gherardi, R. Myopathy and HIV infection. Curr. Opin. Rheumatol., 1995, 7(6), 497-502.
[http://dx.doi.org/10.1097/00002281-199511000-00006] [PMID: 8579969]
[5]
Reisler, R.B.; Murphy, R.L.; Redfield, R.R.; Parker, R.A. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J. Acquir. Immune Defic. Syndr., 2005, 39(2), 159-166.
[PMID: 15905731]
[6]
Dragovic, G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac. J. Trop. Biomed., 2013, 3(6), 422-425.
[http://dx.doi.org/10.1016/S2221-1691(13)60091-X] [PMID: 23730553]
[7]
Carpentier, A.; Patterson, B.W.; Uffelman, K.D.; Salit, I.; Lewis, G.F. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis, 2005, 178(1), 165-172.
[http://dx.doi.org/10.1016/j.atherosclerosis.2004.07.035] [PMID: 15585214]
[8]
Apostolova, N.; Blas-García, A.; Esplugues, J.V. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. Trends Pharmacol. Sci., 2011, 32(12), 715-725.
[http://dx.doi.org/10.1016/j.tips.2011.07.007] [PMID: 21899897]
[9]
Kohler, J.J.; Lewis, W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ. Mol. Mutagen., 2007, 48(3-4), 166-172.
[http://dx.doi.org/10.1002/em.20223] [PMID: 16758472]
[10]
Dykens, J.A.; Will, Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today, 2007, 12(17-18), 777-785.
[http://dx.doi.org/10.1016/j.drudis.2007.07.013] [PMID: 17826691]
[11]
Dolce, V.; Fiermonte, G.; Runswick, M.J.; Palmieri, F.; Walker, J.E. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc. Natl. Acad. Sci. USA, 2001, 98(5), 2284-2288.
[http://dx.doi.org/10.1073/pnas.031430998] [PMID: 11226231]
[12]
Langs-Barlow, A.; Selvaraj, S.; Ogbuagu, O.; Shabanova, V.; Shapiro, E.D.; Paintsil, E. Association of circulating cytochrome c with clinical manifestations of antiretroviral-induced toxicity. Mitochondrion, 2015, 20, 71-74.
[http://dx.doi.org/10.1016/j.mito.2014.11.004] [PMID: 25435346]
[13]
Perez-Manute, P.; Perez-Martinez, L.; Blanco, J.R.; Oteo, J.A. Role of mitochondria in HIV infection and associated metabolic disorders: Focus on non-alcoholic fatty liver disease and lypodystrophy syndrome. Oxid. Med. Cell. Longev., 2013, 2013, 493413
[http://dx.doi.org/10.1155/2013/493413]
[14]
Garg, H.; Mohl, J.; Joshi, A. HIV-1 induced bystander apoptosis. Viruses, 2012, 4(11), 3020-3043.
[http://dx.doi.org/10.3390/v4113020] [PMID: 23202514]
[15]
Worldometers. Ghana Population Live, Available from: http://www.worldometers.info/world-population/ghana-population/
[16]
Ghana AIDS Commission (GAC). Summary of the 2016 HIV sentinel survey report., 2016. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=4&ved=2ahUKEwih4cOE7IveAhVJxxoKHYnXCBIQFjADegQICRAB&url=http%3A%2F%2Fwww.ghanaids.gov.gh%2Fgac1%2Faids_info.php&usg=AOvVaw0e2FBMTQmWHUIfSjJWWk-L
[17]
Cinamon, U. Exceptionally elevated creatine kinase levels in a laryngectomized patient: hypothyroid myopathy. J. Laryngol. Otol., 2004, 118(8), 651-652.
[http://dx.doi.org/10.1258/0022215041917934] [PMID: 15453946]
[18]
Cohen, M.S.; Gay, C.; Kashuba, A.D.M.; Blower, S.; Paxton, L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Intern. Med., 2007, 146(8), 591-601.
[http://dx.doi.org/10.7326/0003-4819-146-8-200704170-00010] [PMID: 17438318]
[19]
Paranjape, R.S. Immunopathogenesis of HIV infection. Indian J. Med. Res., 2005, 121(4), 240-255.
[PMID: 15817942]
[20]
Babu, K.S.; Babu, C.R.; Jyothi, N.R.; Sunita, K. A retrospective study on status of CD4 counts and effect of ART in patients attending VCTC of MGM Hospital, Warangal, Andhra Pradesh. Indian J. Nur. Health Sci., 2014, 3(6), 25-35.
[http://dx.doi.org/10.9790/1959-03632535]
[21]
WHO. Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015. Available from : www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/
[22]
Deavall, D.G.; Martin, E.A.; Horner, J.M.; Roberts, R. Drug-induced oxidative stress and toxicity. J. Toxicol., 2012, 2012, 645460
[http://dx.doi.org/10.1155/2012/645460] [PMID: 22919381]
[23]
Gilks, C.F.; Crowley, S.; Ekpini, R.; Gove, S.; Perriens, J.; Souteyrand, Y.; Sutherland, D.; Vitoria, M.; Guerma, T.; De Cock, K. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet, 2006, 368(9534), 505-510.
[http://dx.doi.org/10.1016/S0140-6736(06)69158-7] [PMID: 16890837]
[24]
Brinkman, K.; Copeland, W. Mitochondrial Toxicity and HIV Disease Meeting Report., 2000. Available from : www.hivforum.org
[25]
Nikhil, G.; Santosh, K.M. Myopathies secondary to anti-retroviral therapy in human immunodeficiency virus positive patients: A Review. J. HIV Retrovirus, 2015, 1(4), 1-5.
[26]
Simpson, D.; Estanislao, L.; Evans, S.; McArthur, J.; Marcus, K.; Truffa, M.; Lucey, B.; Naismith, R.; Lonergan, T.J.; Clifford, D. HIV Neuromuscular Syndrome Study Group. HIV-associated neuromuscular weakness syndrome. AIDS, 2004, 18(10), 1403-1412.
[http://dx.doi.org/10.1097/01.aids.0000131309.70451.fe] [PMID: 15199316]
[27]
Moore, R.D.; Keruly, J.C.; Chaisson, R.E. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS, 2001, 15(5), 617-620.
[http://dx.doi.org/10.1097/00002030-200103300-00011] [PMID: 11316999]
[28]
Oh, J.; Hegele, R.A. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect. Dis., 2007, 7(12), 787-796.
[http://dx.doi.org/10.1016/S1473-3099(07)70287-6] [PMID: 18045561]
[29]
Kowalska, J.D.; Kubicka, J.; Siwak, E.; Pulik, P.; Firląg-Burkacka, E.; Horban, A. Polish Observational Cohort of HIV/AIDS Patients (POLCA) Study Group. Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients. AIDS Res. Ther., 2016, 13(2), 2.
[http://dx.doi.org/10.1186/s12981-015-0084-5] [PMID: 26744599]
[30]
Gardner, K.; Hall, P.A.; Chinnery, P.F.; Payne, B.A. HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies. Toxicol. Pathol., 2014, 42(5), 811-822.
[http://dx.doi.org/10.1177/0192623313503519] [PMID: 24067671]
[31]
Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol., 2007, 35(4), 495-516.
[http://dx.doi.org/10.1080/01926230701320337] [PMID: 17562483]

Rights & Permissions Print Cite
Article Metrics
46
© 2024 Bentham Science Publishers | Privacy Policy